Drug Trial Radar · NCT00460512
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,814
Actual
Start
Apr 25, 2007
Primary completion
Jan 22, 2009
Study completion Mar 4, 2020
Sponsor
- Lead sponsor
- Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 16, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) previously unsuccessfully treated with an oral antipsychotic medication.
Conditions
- Schizophrenia
Interventions
Paliperidone ERDrug
Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least 20 Percent Improvement in Total Positive and Negative Syndrome Scale (PANSS) Score in Those Participants who Transitioned due to Lack of EfficacyTime frame: Endpoint (up to Week 26)
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint (up to Week 26)Time frame: Baseline and endpoint (up to Week 26)
Locations
231 sites in 22 countries. Site status is shown where the registry gives one.
Site not named
Antwerp, Belgium
Site not named
Bertrix, Belgium
Site not named
Dave, Belgium
Site not named
Diest, Belgium
Site not named
Duffel, Belgium
Site not named
Kortenberg, Belgium
Site not named
Liège, Belgium
Site not named
Montignies-sur-Sambre, Belgium
Site not named
Mortsel, Belgium
Site not named
Roeselare, Belgium
Site not named
Saint Denijs-Westrem, Belgium
Site not named
Saint-Servais, Belgium
Site not named
Sint-Truiden, Belgium
Site not named
Tielt, Belgium
Site not named
Waregem, Belgium
Site not named
Bulgaria, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Tzerova Korya, Bulgaria
Site not named
Osijek, Croatia
Site not named
Rijeka, Croatia
Site not named
Split, Croatia
Site not named
Zagreb, Croatia
Site not named
Aalborg, Denmark
Site not named
Elsinore, Denmark
Site not named
Risskov, Denmark
Site not named
Viby J, Denmark
Site not named
Ekenäs, Finland
Site not named
Helsinki, Finland
Site not named
Raahe, Finland
Site not named
Tampere, Finland
Site not named
Bar-le-Duc, France
Site not named
Bordeaux, France
Site not named
Bourg-en-Bresse, France
Site not named
Bully-les-Mines, France
Site not named
Caen, France
Site not named
Chambéry, France
Site not named
Clermont-Ferrand, France
Site not named
Créteil, France
Site not named
Dijon, France
Site not named
Dole, France
Showing 40 of 231 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.